Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab - 180 Life Sciences

Next Previous
Drug Profile

Adalimumab - 180 Life Sciences

Alternative Names: Repurposed anti-TNF therapy - 180 Life Sciences

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 180 Therapeutics
  • Developer 180 Life Sciences; University of Oxford
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dupuytren's contracture; Frozen shoulder
  • No development reported Cognition disorders; Non-alcoholic steatohepatitis

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in United Kingdom
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Cognition-disorders in United Kingdom
  • 07 Aug 2023 180 Life Sciences submits a request to conduct a Type C meeting with the US FDA to seek advice for a phase III trial design and to obtain marketing approval for Dupuytren's contracture

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top